Veterinary Health Product (VHP) Notification in Canada: The 30-Day Rule, the PSL and Your GMP Obligations

Introduction

If you sell vitamins, minerals, or traditional medicines for pets or livestock in Canada, you are almost certainly operating inside a regulated space, whether you realize it or not. Veterinary health products (VHPs) are a distinct, low-risk drug category with their own pathway to market. That pathway is not a full drug approval, but it is not a free pass either. It runs through Health Canada's VHP Notification Program, and it carries a hard timing rule, a mandatory ingredient list, and a real Good Manufacturing Practices (GMP) obligation.

Many companies discover these rules the hard way, often after a product is already packaged, listed with a retailer, or sitting at the border. This guide explains the three requirements that trip up most businesses: the 30-day notification rule, the Permitted Substances List (List C), and the Part 3 GMP duties that sit behind every compliant VHP. It is written for founders, regulatory affairs managers, quality assurance managers, and importers who need a clear, defensible path to market.

What Is a Veterinary Health Product?

Direct answer: A veterinary health product is a low-risk drug in dosage form, such as a tablet, powder, or liquid, used to maintain or promote the health and welfare of companion animals (like dogs and cats) and food-producing animals (like cattle and poultry). VHPs contain ingredients such as vitamins, minerals, and traditional medicines. They are not intended to treat, prevent, or cure disease, and that limitation is the single most important line in the entire framework.

Health Canada created the VHP Notification Program to provide a flexible, risk-appropriate route to market for products with a history of safe use. The program replaced the earlier voluntary Interim Notification Pilot Program (INPP) and became mandatory when the amending regulations, published as SOR/2017-76, came into effect on November 13, 2017.

The defining feature of a VHP is its intended use. Because a VHP maintains or promotes health rather than making a therapeutic claim, it qualifies for the lighter notification pathway instead of a full drug submission. The moment a product claims to treat, prevent, or cure a disease, it stops being a VHP in the eyes of Health Canada and becomes a veterinary drug that requires a Drug Identification Number (DIN) and a far more demanding review.

VHP vs Veterinary Drug: Why the Distinction Matters

Direct answer: A VHP is notified, not approved, and receives a Notification Number rather than a DIN. A veterinary drug undergoes a full pre-market safety and efficacy review. The trigger that pushes a product from the VHP stream into the drug stream is almost always the health claim on the label.

This distinction is where new entrants most often go wrong. A supplement that supports joint mobility in senior dogs can sit comfortably as a VHP. The same product marketed to treat arthritis has made a therapeutic claim and is now an unapproved veterinary drug, which is a compliance problem, not a labelling nuance. The table below summarizes the practical differences.

The 30-Day Rule: Timing Your VHP Notification

Direct answer: Every manufacturer or importer must notify Health Canada at least 30 calendar days before selling a VHP in Canada, at least 30 days before making a change to a VHP already notified, and before importing a VHP into Canada. The 30-day clock is a legal minimum, not a target. You cannot lawfully begin the sale until the period has run.

The 30-day rule sounds simple, and that is exactly why it causes problems. Businesses read 30 days and plan their launch around it, forgetting that the clock only starts once a complete, compliant notification is on file. If Health Canada issues an information request because an ingredient is off-list, a claim is therapeutic, or the label is deficient, the timeline effectively resets while you respond. A launch date built on the bare 30-day minimum leaves no room for that back-and-forth.

For this reason, experienced regulatory teams treat the 30 days as the floor and plan their filing three to six months ahead of the intended launch. That window absorbs formulation review, List C verification, label drafting, and any dialogue with the Veterinary Drugs Directorate, without forcing a delay to a committed retail or distribution date. This planning discipline is at the core of practical regulatory affairs and import/export support, where the goal is to protect the commercial timeline as much as the compliance file.

Three separate 30-day triggers deserve attention:

1. Before first sale. No product may be sold until 30 days after a complete notification is filed.
2. Before a change. If you alter a VHP already on file, for example a formulation, dosage form, or label change, you must notify at least 30 days before the change takes effect.
3. Before import. A VHP must be notified before it is imported into Canada, so importers cannot rely on a foreign approval to clear the border.

The Permitted Substances List (List C)

Direct answer: Every active, homeopathic, and traditional-medicine substance used to make a VHP must appear on List C: Veterinary Health Products, Health Canada's permitted substances list. If an ingredient is not on List C, the product cannot be notified as a VHP until the list is amended through a New Substance Application supported by scientific evidence.

List C is the gatekeeper for VHP formulation. It sets out the substances Health Canada accepts as low risk for the intended species and conditions of use, and in many cases it carries mandatory label statements, dose limits, or species restrictions attached to specific ingredients. Before you finalize a formula, every medicinal ingredient must be checked against List C, and any conditions on that entry must be built into the label and the product specification.

When an ingredient is not listed, you have two realistic options. You can reformulate to use only listed substances, which is usually the faster route to market, or you can file a New Substance Application asking Health Canada to add the ingredient to List C. A New Substance Application must be supported by scientific evidence showing that the ingredient is safe for the intended species and conditions of use and, for food-producing animals, that it does not create an unacceptable risk to people who consume food derived from treated animals. This is a substantive scientific submission, not a formality, and it should be scoped realistically at the planning stage.

Your GMP Obligations Under Part 3

Direct answer: Companies that manufacture, package, label, import, distribute, or store VHPs must comply with the Part 3 Good Manufacturing Practices set out in the Natural Health Products Regulations (SOR/2003-196). This means real quality systems: premises and equipment control, sanitation, specifications, stability data, records, recall procedures, and trained personnel.

The notification itself is only the visible tip of the compliance file. Behind it, Health Canada expects a functioning quality system that satisfies Part 3 GMP. Many businesses underestimate this because the VHP pathway is described as low risk, but low risk refers to the product category, not to the rigour of the quality obligations. A VHP made without stability data, without validated specifications, or without documented sanitation procedures is non-compliant even if the notification was accepted.

Part 3 GMP expectations for VHPs typically include:

• Specifications for finished products and raw materials, with defined acceptance criteria.
• Stability data to support the assigned expiry date and storage conditions.
• Premises, equipment, and sanitation controls that prevent contamination and mix-ups.
• Standard operating procedures (SOPs) covering the core quality activities, kept current and followed in practice.
• Records that let you reconstruct the history of every lot, including testing and release.
• Recall and complaint handling systems that can act quickly if a problem emerges.
• Trained personnel with defined responsibilities for quality decisions.

Because the VHP GMP standard is the same Part 3 framework used for natural health products, businesses already active in the NHP space have a head start. If you are building from scratch, structured quality assurance and GMP support shortens the path considerably, and a focused GMP audit will surface gaps before an inspector does. The same GMP disciplines that protect a natural health product licence apply directly to VHPs.

Labelling Rules Every VHP Must Follow

Direct answer: A VHP label must carry the bilingual statement "Veterinary health product / Produit de sante animale," follow the labelling rules of the Food and Drug Regulations, and include any mandatory statements specified on List C for the ingredients used. The label must also match the product as notified.

Labelling is where notification compliance becomes visible to inspectors and consumers alike. The mandatory bilingual identifier tells the market and the regulator that the product is a notified VHP, not an approved drug. Beyond that identifier, the label must respect the general labelling requirements of the Food and Drug Regulations and reproduce any ingredient-specific cautions or dosing statements attached to the relevant List C entries.

A frequent finding is a mismatch between the notified product and the marketed label, for example a claim, directions-for-use, or an ingredient that appears on the shelf but not on the notification. Any such gap undermines the notification and can trigger compliance action. A disciplined label review against both the Food and Drug Regulations and the List C conditions, completed before printing, prevents costly relabelling and re-notification later.

Adverse Reaction Reporting and Ongoing Compliance

Direct answer: VHP notifiers must monitor and report serious adverse drug reactions to Health Canada. As a general Health Canada expectation, serious adverse reactions should be reported within 15 calendar days of becoming aware of them, and notifiers must keep records that support post-market surveillance.

Getting to market is a milestone, not the finish line. A VHP notification creates continuing obligations. You must actively monitor safety information, maintain records, and report serious adverse drug reactions so that Health Canada can detect uncommon or severe reactions, update safety information, and, if necessary, remove unsafe products from the market. A robust adverse-reaction SOP, with clear roles and a defined reporting timeline, is a core part of a defensible VHP quality system and something inspectors will expect to see.

Post-market compliance also includes keeping your notification current. Any material change to the product, as noted above, requires a fresh 30-day notification before it takes effect. Treating the notification as a living record rather than a one-time filing is what keeps a product lawfully on the market over time.

What Does a VHP Notification Cost?

Direct answer: VHP notifications are subject to a cost-recovery fee under the Fees in Respect of Drugs and Medical Devices Order. The fee is indexed to the Consumer Price Index each year. It was approximately CAD $562 effective April 1, 2024 and approximately CAD $578 effective April 1, 2025. Confirm the current figure on Health Canada's fee pages before filing, because it is updated annually.

Two features of the fee structure matter for planning. First, the fee is payable regardless of outcome. If a notification is refused because of a non-permitted ingredient, a therapeutic claim, a labelling deficiency, or a failure to answer an information request, the fee is not refunded. That makes front-end quality checks a direct cost-avoidance measure. Second, Health Canada applies a 30-day performance standard to notification review. If the department does not meet that standard, the applicable fee is reduced by 25 percent.

Small businesses may also qualify for relief. Under Health Canada's cost-recovery framework, eligible small businesses can receive a reduction on applicable fees and, in some cases, a waiver for a first notification. Because eligibility and amounts are defined by the fee order and updated over time, verify the current small-business provisions when you budget. The exact dollar amount is indexed annually, so confirm it against the live Health Canada fee pages at filing time.

VHP Notification Compliance Checklist

Use this checklist as a pre-filing gate. Every item should be closed before you submit.

• Confirm the product is a VHP, not a veterinary drug, based on its intended use and claims.
• Verify every medicinal, homeopathic, and traditional-medicine ingredient against List C.
• Identify and comply with any List C conditions, such as dose limits or mandatory statements.
• File a New Substance Application if any ingredient is not on List C, and scope the evidence early.
• Build a Part 3 GMP quality system: specifications, stability, SOPs, records, sanitation, recall.
• Draft the label with the bilingual Veterinary health product / Produit de sante animale statement.
• Confirm the label follows Food and Drug Regulations rules and matches the notified product.
• Prepare an adverse-reaction reporting SOP with a defined 15-day timeline.
• Budget the current notification fee and confirm it on Health Canada's fee pages.
• File at least 30 days before sale or import, ideally 3 to 6 months ahead of launch.
• Track the Notification Number and keep the file current for any future changes.

Common Mistakes That Delay or Sink a VHP Notification

Experience across regulated product filings shows the same errors recurring. Avoiding them is often the difference between an on-time launch and a stalled one.

1. Making a therapeutic claim. Marketing language that treats, prevents, or cures disease reclassifies the product as a veterinary drug and voids the VHP pathway.
2. Using an off-list ingredient. A single substance that is not on List C leads to refusal, with the fee still payable.
3. Planning to the bare 30 days. Building a launch around the legal minimum leaves no room for information requests, which reset the timeline in practice.
4. Treating GMP as optional. Low risk describes the product, not the quality obligations. Missing stability data or SOPs is a common gap.
5. Label and notification mismatch. A claim or ingredient on the shelf that does not match the notification undermines compliance.
6. Ignoring post-market duties. Failing to report serious adverse reactions or to re-notify changes creates ongoing exposure.
7. Assuming a foreign approval clears the border. A VHP must be notified before import, regardless of its status in another country.

Frequently Asked Questions

Is a veterinary health product a drug?

Yes. A VHP is a low-risk drug in dosage form. It is regulated by Health Canada through the VHP Notification Program rather than through a full drug submission, but it remains a drug and carries GMP and reporting obligations.

How much does a VHP notification cost?

The notification carries a cost-recovery fee that is indexed to inflation each year. It was about CAD $562 effective April 1, 2024 and about CAD $578 effective April 1, 2025. Because the amount is updated annually, confirm the current figure on Health Canada's fee pages before filing.

What is a VHP notification number?

When Health Canada accepts a notification, it issues a Notification Number (NN). This number identifies the notified product and is the VHP equivalent of the role a Drug Identification Number plays for a full veterinary drug.

Do I need GMP for a VHP?

Yes. Anyone who manufactures, packages, labels, imports, distributes, or stores a VHP must comply with the Part 3 Good Manufacturing Practices in the Natural Health Products Regulations, including specifications, stability, records, sanitation, and recall systems.

Can a VHP make a health claim?

A VHP may make claims to maintain or promote health and welfare, but it cannot claim to treat, prevent, or cure disease. A therapeutic claim reclassifies the product as a veterinary drug requiring a full submission and a DIN.

What happens if my ingredient is not on the Permitted Substances List?

You can reformulate using only listed substances, which is usually faster, or file a New Substance Application asking Health Canada to add the ingredient to List C. That application must be supported by scientific evidence of safety for the intended species and, for food-producing animals, for people who eat food from treated animals.

How MFLRC Can Help

VHP notification looks straightforward on paper and turns out to be detail-heavy in practice. MF License & Regulatory Consultants helps companies move from formulation to a compliant, on-time launch without guesswork.

We support you across the full pathway. Our team confirms your product's classification, screens the complete ingredient deck against List C, and flags where a New Substance Application will be required so there are no surprises at filing. We prepare and file the VHP notification, manage the 30-day timeline against your launch date, and handle any information requests from the Veterinary Drugs Directorate.

Behind the filing, we build the quality system it depends on. That includes Part 3 GMP gap assessments, SOP development, specifications and stability planning, and label review against both the Food and Drug Regulations and your List C conditions. We also set up practical adverse-reaction reporting procedures so your post-market obligations are covered from day one. Importers benefit from targeted import and licensing guidance, and companies preparing for scrutiny can draw on our audit and inspection-readiness services and the lessons in our guide to acing a Health Canada audit.

Conclusion

The VHP Notification Program gives low-risk animal health products a genuinely lighter route to market, but lighter is not the same as loose. Three requirements decide whether your launch goes smoothly: notifying Health Canada at least 30 days ahead, keeping every ingredient on List C, and standing up a real Part 3 GMP quality system. Layer on accurate bilingual labelling, disciplined adverse-reaction reporting, and a correctly budgeted fee, and you have a defensible file that holds up to scrutiny. Plan the work three to six months out, close the checklist before you file, and treat the notification as a living record. Do that, and the pathway works the way it was designed to, letting you commercialize responsibly while your compliance foundation stays solid.

Sources and References

• Health Canada, Veterinary Health Products (program overview, 30-day rule, List C, Part 3 GMP, labelling, adverse-reaction reporting)
• Health Canada, List C: Veterinary Health Products (Permitted Substances List)
• Natural Health Products Regulations (SOR/2003-196), Part 3 Good Manufacturing Practices
• Regulations Amending the Food and Drug Regulations (Veterinary Drugs, Antimicrobial Resistance), SOR/2017-76
• Health Canada, Fees for Veterinary Drugs
• Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124)